Celltrion finally won the patent dispute over Mabthera (Rituximab). Celltrion has been able to completely overcome the patent risk of Mabthera biosimilar Truxima by confirming the victory in the lawsuit that lasted more than five years.

On the morning of the 25th, the Supreme Court ruled in an appeal for invalidation of patent registration filed by Biogen. It also took the side of Celltrion.

It is Mabthera's use patent. This article is about how to treat hematologic malignancies associated with a high number of circulating tumor cells by administering chimeric anti-CD20 monoclonal antibody.

Including this, Biogen holds five patents of Mabthera. However, the remaining 4 pat